ScreenerHero

RCUS Arcus Biosciences, Inc.

NYSE · US · Healthcare · Biotechnology · arcusbio.com
24.52USD+0.99%Mkt Cap: 3.12B $P/E: —

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap3.12B USD
Enterprise Value2.63B USD
Revenue (TTM)117.00M USD
Gross Profit-380.00M USD
Net Income (TTM)-353.00M USD
Revenue/Share0.98 USD
Last Price24.52 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees601
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-7.17
PEG—
EV/EBITDA-5.52
EV/Revenue22.46
P/S26.42
P/B6.64
EPS (TTM)-3.84
EPS (Forward)-3.38
52W Range
13.2161% of range31.74
52W High31.74 USD
52W Low13.21 USD
Profitability
Gross Margin0.00%
Oper. Margin-234.15%
EBITDA Margin0.00%
Profit Margin-142.91%
ROE-55.94%
ROA-30.99%
Growth
Revenue Growth-74.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF-482.00M USD
CapEx (TTM)2.00M USD
FCF Margin-231.30%
FCF Yield-8.67%
Net Debt-464.00M USD
Net Debt/EBITDA0.97
Balance Sheet
Debt/Equity0.18
Current Ratio3.82
Quick Ratio3.75
Book Value/Sh3.65 USD
Cash/Share5.51 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)39.91 USD
Upside (mean)+62.8%
Target Range23.00 USD – 47.00 USD
23.00+62.8% to mean47.00
# Analysts11
Ownership
Shares Out.127.33M
Float90.53M
Insiders28.80%
Institutions74.92%
Short Interest
Short Ratio9.4d
Short % Float17.71%
Short % Out.10.85%
Shares Short13.81M
Short (prev mo.)13.85M
Technical
SMA 5027.72 (-11.5%)
SMA 20024.79 (-1.1%)
Beta0.94
S&P 52W Chg15.78%
Avg Vol (30d)1.53M
Avg Vol (10d)1.44M
Technical Indicators
RSI (14)39.2
MACD-0.8801
MACD Signal-0.8698
MACD Hist.-0.0103
BB Upper26.72 USD
BB Middle25.18 USD
BB Lower23.63 USD
BB Width12.26%
ATR (14)1.200 USD
Vol Ratio (20d)0.91x